Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 7:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Breast Cancer
Interventions
Molecular Breast Imaging
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Recruiting No phase listed Observational

Safe and Explainable AI

NCT06694181
Conditions
Artifical Inteligence, Cardiology, Breast Cancer, Sepsis
Interventions
AI-PERSONALIZED CLINICAL DECISION SUPPORT
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
300,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Michael O'Connor
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Breast Disease
Interventions
Not listed
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2014
U.S. locations
3
States / cities
Liverpool, New York • Syracuse, New York
Completed Not applicable Interventional Accepts healthy volunteers Results available

Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts

NCT00620373
Conditions
Breast Cancer
Interventions
Molecular Breast Imaging, Conventional Mammography, Technetium (99mTc) sestamibi
Device · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years and older · Female only
Enrollment
969 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Breast Cancer, Cancer of Breast, Cancer of the Breast
Interventions
Breast-conserving surgery (BCS), Cavity shave margins (CSM), BREAST-Q Questionnaire, 3-D breast imaging, Indocyanine green, Intraoperative imaging device, Peripheral blood draw
Procedure · Behavioral · Device + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Breast Cancer
Interventions
Tc99m sestamibi
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Suspicious Breast Lesion for Which Biopsy is Scheduled
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 95 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Active, not recruiting Not applicable Interventional

Tc99m Sestamibi Molecular Breast Imaging

NCT02324387
Conditions
Breast Cancer
Interventions
Molecular Breast Imaging (MBI), Tc99m sestamibi
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
Houston, Texas
Completed Not applicable Interventional Accepts healthy volunteers

Molecular Breast Imaging in Women With Atypia and LCIS

NCT00620087
Conditions
Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma in Situ
Interventions
Molecular Breast Imaging, Screening Mammography
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Breast Cancer
Interventions
Molecular Breast Imaging
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 80 Years · Female only
Enrollment
228 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
Interventions
Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab, Pertuzumab and Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab, Ivonescimab (20mg/kg Q3W)
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2031
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more
Conditions
Breast Cancer
Interventions
Bevacizumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
HER2 Positive Breast Carcinoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Copper Cu 64-DOTA-Trastuzumab, Laboratory Biomarker Analysis, Pertuzumab, Positron Emission Tomography, Therapeutic Conventional Surgery, Trastuzumab
Radiation · Other · Biological + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
Duarte, California
Conditions
Breast Cancer
Interventions
Lapatinib
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed No phase listed Observational Accepts healthy volunteers

Hormonal Effects on Tc-99m Sestamibi Uptake in the Breast

NCT00943527
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 45 Years · Female only
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Molecular Imaging
Interventions
Meal, Exercise, Sestamibi, Caffeine Tablet, External Heating
Dietary Supplement · Other · Radiation + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 70 Years · Female only
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Completed No phase listed Observational

Pre-biopsy With Dynamic Acquisitions

NCT00943644
Conditions
Breast Cancer
Interventions
Molecular Breast Imaging (MBI), CZT semiconductor detectors
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Breast Cancer
Interventions
Positron Emission Mammography, Magnetic Resonance Imaging
Procedure
Lead sponsor
Naviscan PET Systems
Industry
Eligibility
25 Years and older · Female only
Enrollment
472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
6
States / cities
Los Angeles, California • San Diego, California • Boca Raton, Florida + 3 more
Conditions
Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Interventions
Abemaciclib, Biopsy, Bone Scan, Echocardiography, Exemestane, Gemcitabine, Letrozole, Multigated Acquisition Scan, Osimertinib, Pemetrexed, Survey Administration, Tamoxifen, Biospecimen Collection
Drug · Procedure · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Not yet recruiting Not applicable Interventional

Molecular Breast Imaging (MBI)-Guided Biopsy

NCT07114679
Conditions
Breast Cancer Detection, Breast Neoplasm, Molecular Imaging, Biopsy, Dense Breasts
Interventions
Molecular Breast Imaging, MBI-guided biopsy
Device
Lead sponsor
Smart Breast Corp.
Industry
Eligibility
21 Years and older · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Breast Cancer, Healthy, no Evidence of Disease
Interventions
exercise intervention, counseling intervention, gas chromatography, immunoenzyme technique, immunologic technique, laboratory biomarker analysis, mass spectrometry, physiologic testing, questionnaire administration, survey administration, dual x-ray absorptometry, magnetic resonance imaging, study of high risk factors
Behavioral · Other · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Not applicable Interventional Accepts healthy volunteers Results available

Low Dose Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts

NCT01925170
Conditions
Breast Cancer
Interventions
Molecular Breast Imaging, Conventional Mammography, Technetium (99mTc) sestamibi
Device · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older · Female only
Enrollment
1,638 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Half-Dose Molecular Breast Imaging With Wide Beam Reconstruction Processing

NCT01653964
Conditions
Breast Cancer
Interventions
Molecular breast imaging
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older · Female only
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota